Bio-Techne Corp

TECH: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
Q<LOCK|D$L%%LOCK|VzGQsJ%

Bio-Techne Earnings: Hit by Lower Cell Therapy Demand

Bio-Techne reported a year-on-year organic revenue decline of 1% for the first quarter of its fiscal 2026, which included a 3% organic decline in protein sciences and 3% organic growth in diagnostics and spatial biology.

Sponsor Center